Colorectal Cancer

General Cancer

Axel Grothey, MD, discusses the results from the safety lead-in phase of the BEACON CRC trial investigating the triplet regimen of BRAF inhibitor encorafenib, MEK inhibitor binimetinib, and anti-EGFR antibody cetuximab in&nbsp;patients with&nbsp;<em>BRAF</em>V600E-mutant metastatic colorectal cancer.

A&nbsp;direct-to-consumer genetic test has been approved by the FDA for providing a&nbsp;risk report on MUTYH-associated polyposis, a hereditary colorectal cancer syndrome, according to&nbsp;23andMe, the personal genetics company that manufactures the test.<br /> &nbsp;

Michael J. Overman, MD, discusses the data presented at the 2019 Gastrointestinal Cancers Symposium for the phase II CheckMate-142 in previously treated patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer.

Treatment with&nbsp;durvalumab demonstrated&nbsp;objective responses in approximately one-fourth of patients with&nbsp;microsatellite instability-high advanced solid tumors, including colorectal cancer, according to data from 2 preliminary clinical trials.

When&nbsp;durvalumab and tremelimumab were combined with&nbsp;best supportive care, the combination reduced the risk of progression or death by 28% compared with best supportive care alone, according to findings from a phase II clinical trial.&nbsp;

Updated findings from the&nbsp;safety lead-in phase of the BEACON CRC trial showed an estimated survival time beyond historic controls from treatment with a triplet combination of&nbsp;encorafenib, binimetinib, and cetuximab for patients with&nbsp;<em>BRAF&nbsp;</em>V600E-mutant metastatic colorectal cancer.&nbsp;

Pashtoon M. Kasi, MD, MBBS, MS, discusses how the triplet regimen of the BRAF inhibitor encorafenib, the MEK inhibitor binimetinib, and the EGFR inhibitor cetuximab, will impact the treatment landscape for patients with metastatic colorectal cancer.

Pashtoon M. Kasi, MD, MBBS, MS,&nbsp;discusses recent advances with individualized medicine in CRC, as well as the unmet needs that still exist in this area.

Due to the significant decline in smoking and an increase in advances for early cancer detection and screening, the cancer death rate has declined 27% in the United States from 1991 to 2016, according to the American Cancer Society&rsquo;s annual report on cancer rates.

Al B. Benson III, MD, FACP, FASCO, professor of medicine at Northwestern University, shares advice to community oncologists treating patients with colorectal cancer. He emphasizes looking carefully at different patient characteristics before making treatment decisions.

The first patient has been enrolled in the pivotal phase III AGENT trial, which is investigating arfolitixorin in combination with 5-fluorouracil, oxaliplatin, and bevacizumab compared with FOLFOX plus bevacizumab in patients with metastatic colorectal cancer, according to Isofol Medical AB, the company developing arfolitixorin.

Novel immunomodulatory agent pixatimod combined with nivolumab, a PD-1 inhibitor, may benefit patients with advanced bowel cancers, including a small subset of those with colorectal cancer considered to be microsatellite stable.

Real-world dosing data for regorafenib in patients with metastatic colorectal cancer was presented at the 2018 ESMO Congress from the prospective, observational CORRELATE study.

Over the past 15 years, cancer therapy has been revolutionized through the development and use of antibodies that block T-cell inhibition via immune checkpoint, such as CTLA-4 and PD-1.

Wasif Saif, MD, MBBS, recently talked about the treatment considerations and decisions he makes when treating patients with colorectal cancer. Saif explained his treatment decisions based on a case scenario during a <em>Targeted Oncology</em> live case-based peer perspectives presentation.

During a <em>Targeted Oncology </em>live case-based peer perspectives presentation, L. Wayne Keiser, MD, talked about the treatment considerations and decisions he makes when treating patients with colorectal cancer. Keiser, a medical oncologist at St. Joseph Health Medical Group, Santa Rosa, California, explained his treatment decisions for the based on a case scenario of a patient with <em>KRAS</em>-mutated metastatic CRC.

Tanios Bekaii-Saab, MD, discusses how community oncologists can play an important role in the advancement of gastrointestinal (GI) cancers despite not having access to major trials.

Cathy Eng, MD, discusses the current paradigm of GI cancers, specifically sharing insight on colorectal cancer and hepatocellular carcinoma.<br /> &nbsp;